By addressing these gaps, this study aims to provide novel insights into the biology of CSCs in CRC and highlight the potential of CD133-positive CTCs as a robust biomarker for improving prognostic accuracy and guiding personalized treatment strategies. The gene discussed is PROM1; the disease is colorectal carcinoma.